Yeah, I found that, it's one of the links at the bottom here:
Message 20942717
I can't confirm anything since then, either. No other assignee yet, so presumably Columbia still owns it. I was wondering if this was covered by any agreement between INGN and Columbia, since INGN's been linked with Fisher's lab for a number of years. So I was hoping INGN had first dibs on this, as it seems pretty interesting. A look in the S1/A suggests not (after all, Fisher does have other projects, PEG-Prom is apparently one of them). The original agreement covered only MDA-7 for gene therapy, as far as I can tell, and was between Columbia and a company that Corixa bought. Corixa then licensed out that IP to INGN.
Anyhow, not of immediate relevance. How about some H&N cancer results or sumthin?
Cheers, Tuck |
